Relapsed/Refractory, High Risk Hematologic Malignancies
1 clinical trials · Condition
◉ Watch Relapsed/Refractory, High Risk Hematologic Malignancies
| Record | Firm | Date |
|---|---|---|
| CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma (NCT05212584) | iCell Gene Therapeutics | 2022-07-01 |
Track Relapsed/Refractory, High Risk Hematologic Malignancies automatically
Every clearance here is in the API, with alerts when new ones post.